Literature DB >> 16757018

Effects of central neurokinin-1 receptor antagonism on cocaine- and opiate-induced locomotor activity and self-administration behaviour in rats.

Franca M Placenza1, Paul J Fletcher, Franco J Vaccarino, Suzanne Erb.   

Abstract

The neuropeptide substance P (SP) and its preferred receptor, the neurokinin-1 (NK-1) receptor, have been implicated in some of the reward-related behavioural effects of abused drugs, including psychostimulants and opiates. The first objective of the present series of experiments was to assess the role of the NK-1 receptor in two reward-related behavioural effects of cocaine: locomotor activity and self-administration. In tests for locomotor activity, rats were given intracerebroventricular (ICV) infusions of the selective NK-1 receptor antagonist, GR82334 (0, 10, 50 pmol), prior to systemic injections of cocaine. In self-administration experiments, rats were trained to self-administer cocaine on a fixed-ratio 5 (FR5) schedule of reinforcement. Following acquisition of stable responding, animals were pretreated with GR82334 (0, 2, 10, 50 pmol; ICV) prior to subsequent self-administration sessions. Based on evidence suggesting a potentially selective role for NK-1 receptors in opiate reward, we also examined the effects of GR82334 on morphine-induced locomotor activity and heroin self-administration. Results showed that GR82334 had no effect on cocaine-induced locomotor activity or cocaine self-administration, but attenuated morphine-induced locomotor activity and increased heroin self-administration. These findings suggest that endogenous activity at NK-1 receptors may play a specific role in opiate-induced, but not cocaine-induced, locomotor activation and reinforcement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757018     DOI: 10.1016/j.pbb.2006.04.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking.

Authors:  Jesse R Schank; Courtney E King; Hui Sun; Kejun Cheng; Kenner C Rice; Markus Heilig; David Weinshenker; Jason P Schroeder
Journal:  Neuropsychopharmacology       Date:  2013-10-31       Impact factor: 7.853

3.  Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.

Authors:  Padmanabhan Mannangatti; Santhanalakshmi Sundaramurthy; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  Psychopharmacology (Berl)       Date:  2016-12-24       Impact factor: 4.530

Review 4.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

5.  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Authors:  Jermaine D Jones; Taylor Speer; Sandra D Comer; Stephen Ross; John Rotrosen; Malcolm S Reid
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

6.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Authors:  T M Largent-Milnes; S W Brookshire; D P Skinner; K E Hanlon; D Giuvelis; T Yamamoto; P Davis; C R Campos; P Nair; S Deekonda; E J Bilsky; F Porreca; V J Hruby; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2013-07-16       Impact factor: 4.030

Review 7.  The pharmacology of neurokinin receptors in addiction: prospects for therapy.

Authors:  Alexander J Sandweiss; Todd W Vanderah
Journal:  Subst Abuse Rehabil       Date:  2015-09-07

Review 8.  Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.

Authors:  B Jupp; J W Dalley
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.